Venlafaxine and clonidine were statistically superior to placebo.
One of the most common complaints from breast cancer survivors is bothersome hot flashes caused by many adjuvant therapies. Accordingly, many strategies (both hormonal and nonhormonal) have been tested for efficacy in attenuating hot flash frequency and severity: Agents including antidepressants, anticonvulsants, antihypertensives, and progestins have been evaluated with varying results (JW Womens Health Feb 26 2009). However, few studies have used validated assessment tools and sufficient numbers of participants to arrive at clinically useful conclusions.
Dutch investigators conducted a randomized, double-blind, placebo-controlled trial in 102 patients with histories of breast cancer who had natural menopause, chemotherapy-induced menopause…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)